NEWS RELEASE


Thermedical™ Announces Series A Financing Round
 

Innovative Ablation Therapy May Significantly Alter Cancer Treatment

 

SOMERVILLE, Mass., March 20, 2012 – Thermedical™, a privately held company developing proprietary thermal therapy equipment for numerous clinical conditions, today announced that it closed $1.5 million in Series A funding with a private investor, Samuel H. Maslak, Sc.D. The financing will fund continued research and development, and additional patent filings; it will also help the company achieve 510(k) regulatory clearance from the U.S. Food & Drug Administration (FDA).

Thermedical™ is developing preclinical prototypes for a Saline-Enhanced Radio Frequency (SERF™) ablation system for treating malignant solid tissue, such as liver cancer, and for difficult-to-treat cardiac arrhythmias, such as ventricular tachycardia (VT).

 

“I am investing in Thermedical™ and joining its Board of Directors because I believe the SERF™ Ablation Technology will dramatically improve the efficacy of ablation therapy,”  said Dr. Maslak, chairman of the board of directors at Thermedical™. “I project that this revolutionary technology will alter the course of treatment for patients with liver cancer and other solid tumors, and that it will deliver a cost-effective cure for VT.

“It’s clear to me that Thermedical™ will become an important, highly profitable company developing and selling thermal therapies. Simply put, SERF™ Ablation Technology will be a game-changer in both cancer and VT treatment.”

 

Samuel H. Maslak, Sc.D, Chairman of Board


About Thermedical™
 

Based in Somerville, Mass., Thermedical™ is a privately held company founded by Michael G. Curley, Ph.D., andPatrick S. Hamilton, Ph.D. Under multiple National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Grants and a Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) Award, Thermedical™ is developing thermal ablation systems to treat previously untreatable cancer and cardiac arrhythmias. The ablation therapy system is designed to increase survival and improve quality of life for liver cancer patients, and be a cure for VT.

 

SERF Ablation is a trademark of Thermedical.

 

The Thermedical® Ablation System is 510(k) cleared for the coagulation and ablation of soft tissue during percutaneous, laparoscopic and intraoperative surgical procedures.  Use of the Thermedical Ablation System for any specific soft tissue indication has not been evaluated or approved by the US FDA.

Use of the Thermedical Ablation System for the treatment of VT is investigational and is not approved for use or sale in any market.

150 Bear Hill Road,  Waltham, MA 02451-1036
781.373.3688

©Copyright Thermedical, Inc. 2011-2015. All Rights Reserved. | Copyright and Trademark Notice 
Thermedical® and Durablate™ are trademarks of Thermedical, Inc. registered in the United States and Internationally.